CY1120086T1 - Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικου - Google Patents
Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικουInfo
- Publication number
- CY1120086T1 CY1120086T1 CY20181100166T CY181100166T CY1120086T1 CY 1120086 T1 CY1120086 T1 CY 1120086T1 CY 20181100166 T CY20181100166 T CY 20181100166T CY 181100166 T CY181100166 T CY 181100166T CY 1120086 T1 CY1120086 T1 CY 1120086T1
- Authority
- CY
- Cyprus
- Prior art keywords
- administration
- ghb
- monocarboxylate
- hydroxybutyrate
- transports
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Toxicology (AREA)
Abstract
Μία πραγματοποίηση της παρούσας εφεύρεσης είναι να βελτιώνεται η ασφάλεια και η αποτελεσματικότητα της χορήγησης του GHB ή άλατος αυτού σε έναν ασθενή. Έχει ανακαλυφθεί ότι η ταυτόχρονη χορήγηση ενός αναστολέα MCT, όπως δικλοφενάκης, βαλπροϊκού ή ιμπουπροφένης, θα επηρεάζει χορήγηση GHB. Για παράδειγμα, έχει ανακαλυφθεί ότι η δικλοφενάκη μειώνει το αποτέλεσμα του GHB στο σώμα, προκαλώντας με τον τρόπο αυτό πιθανώς επισφαλή κατάσταση. Περαιτέρω, έχει ανακαλυφθεί ότι βαλπροϊκό αυξάνει το αποτέλεσμα του GHB επί του σώματος, πιθανώς προκαλώντας με τον τρόπο αυτό επισφαλή κατάσταση.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771557P | 2013-03-01 | 2013-03-01 | |
US201361777873P | 2013-03-12 | 2013-03-12 | |
US13/837,714 US9050302B2 (en) | 2013-03-01 | 2013-03-15 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US13/873,000 US8952029B2 (en) | 2013-03-01 | 2013-04-29 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US13/872,997 US8772306B1 (en) | 2013-03-01 | 2013-04-29 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
PCT/US2014/019217 WO2014134380A1 (en) | 2013-03-01 | 2014-02-28 | Administration of gamma hydroxybutyrate with monocarboxylate transporters |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120086T1 true CY1120086T1 (el) | 2018-12-12 |
Family
ID=51031733
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100166T CY1120086T1 (el) | 2013-03-01 | 2018-02-09 | Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικου |
CY20201100199T CY1122992T1 (el) | 2013-03-01 | 2020-03-06 | Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικου |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100199T CY1122992T1 (el) | 2013-03-01 | 2020-03-06 | Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικου |
Country Status (22)
Country | Link |
---|---|
US (10) | US9050302B2 (el) |
EP (3) | EP3335708B1 (el) |
JP (1) | JP6433440B2 (el) |
KR (1) | KR102239042B1 (el) |
CN (2) | CN105073106A (el) |
AU (1) | AU2014223373B2 (el) |
BR (1) | BR112015021012A8 (el) |
CA (1) | CA2902948C (el) |
CY (2) | CY1120086T1 (el) |
DK (2) | DK3335708T3 (el) |
ES (2) | ES2775779T3 (el) |
HK (2) | HK1215539A1 (el) |
HR (1) | HRP20200215T1 (el) |
IL (1) | IL240874B (el) |
LT (1) | LT3335708T (el) |
MX (1) | MX2015011242A (el) |
PL (2) | PL2961399T3 (el) |
PT (2) | PT3335708T (el) |
SG (1) | SG11201505029QA (el) |
SI (1) | SI3335708T1 (el) |
TW (1) | TWI619492B (el) |
WO (1) | WO2014134380A1 (el) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) * | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
CA3207643A1 (en) | 2015-09-23 | 2017-03-30 | XWPharma Ltd. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
CA3036071A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
KR20200016889A (ko) | 2017-06-02 | 2020-02-17 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
EP3661911A4 (en) | 2017-07-31 | 2021-04-14 | Jazz Pharmaceuticals Ireland Limited | CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF |
KR20200053570A (ko) * | 2017-09-12 | 2020-05-18 | 오비드 테라퓨틱스 인크. | 기면증의 치료에서 가복사돌의 사용 |
WO2020106735A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
TW202135790A (zh) | 2019-12-24 | 2021-10-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | Ghb給藥 |
TW202139986A (zh) * | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
EP4135680A1 (en) * | 2020-04-16 | 2023-02-22 | Flamel Ireland Limited | Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium |
WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
JP2023544420A (ja) | 2020-10-05 | 2023-10-23 | エックスダブリューファーマ リミテッド | ガンマ-ヒドロキシ酪酸誘導体の調節放出組成物 |
WO2022076824A1 (en) | 2020-10-08 | 2022-04-14 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
CA3195856A1 (en) | 2020-10-16 | 2022-04-21 | Franck SKOBIERANDA | Treatment methods using ghb |
EP4308086A1 (en) | 2021-03-19 | 2024-01-24 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
WO2023062018A1 (en) | 2021-10-11 | 2023-04-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
WO2023135150A1 (en) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE237309C (el) | ||||
US797171A (en) | 1904-08-04 | 1905-08-15 | Antonio Cerruti | Fruit-washer. |
GB922029A (en) | 1960-05-19 | 1963-03-27 | Equilibre Biolog L | Therapeutic composition |
US3051619A (en) | 1960-05-19 | 1962-08-28 | Equilibre Biolog L | 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia |
GB971700A (en) | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
FR2442M (fr) | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
FR2383920A1 (fr) | 1977-03-15 | 1978-10-13 | Labaz | Procede de preparation d'un derive d'acetonitrile et derive obtenu par ce procede |
US4155929A (en) | 1977-05-25 | 1979-05-22 | Labaz | Process for the preparation of an acetonitrile derivative |
EP0044801B1 (de) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel |
JPS61186319A (ja) * | 1985-02-12 | 1986-08-20 | Res Dev Corp Of Japan | 睡眠覚醒調節剤 |
DD237309A1 (de) | 1985-05-15 | 1986-07-09 | Berlin Chemie Veb | Verfahren zur herstellung eines lagerstabilen natriumsalzes der gamma-hydroxybuttersaeure |
IT1217783B (it) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
US4983612A (en) | 1989-10-05 | 1991-01-08 | American Home Products Corporation | Antihypertensive benzopyran derivatives |
DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
IT1271403B (it) | 1993-03-26 | 1997-05-28 | Ct Lab Farm Srl | Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi |
US5833599A (en) | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
US5762955A (en) | 1994-02-04 | 1998-06-09 | Smith; Stephen Jay | Method for application and maintenance of medication on body tissue |
US7072840B1 (en) | 1994-10-28 | 2006-07-04 | Cybear, L.L.C. | Prescription management system |
US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
US5758095A (en) | 1995-02-24 | 1998-05-26 | Albaum; David | Interactive medication ordering system |
US6112182A (en) | 1996-01-16 | 2000-08-29 | Healthcare Computer Corporation | Method and apparatus for integrated management of pharmaceutical and healthcare services |
US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
US6067524A (en) | 1999-01-07 | 2000-05-23 | Catalina Marketing International, Inc. | Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data |
US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
US6383764B1 (en) * | 2000-04-28 | 2002-05-07 | The Regents Of The University Of California | Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP) |
EP1325014B1 (en) | 2000-09-22 | 2012-05-23 | JPI Commercial, LLC | Gamma-hydroxybutyrate compositions containing carbohydrate carriers |
US6315720B1 (en) * | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
RU2232012C1 (ru) | 2003-06-02 | 2004-07-10 | Иркутский государственный медицинский университет | Способ лечения бруксизма |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
KR20070085838A (ko) | 2004-11-10 | 2007-08-27 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 운동 장애의 치료 방법 |
US20110145018A1 (en) * | 2005-03-21 | 2011-06-16 | Fotsch Edward J | Drug and medical device safety and support information reporting system, processing device and method |
WO2006124609A2 (en) * | 2005-05-16 | 2006-11-23 | Joseph Johnson | Methods and compositions for treating arg |
US8889635B2 (en) | 2008-09-30 | 2014-11-18 | The Regents Of The University Of Michigan | Dendrimer conjugates |
US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
FR2938431B1 (fr) * | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
JP5925766B2 (ja) | 2010-05-04 | 2016-05-25 | ジャズ、ファーマシューティカルズ、インコーポレイテッドJazz Pharmaceuticals Inc. | γ−ヒドロキシ酪酸塩の即時放出製剤および剤形 |
WO2012037457A1 (en) | 2010-09-16 | 2012-03-22 | Cornell University | Use of adenosine receptor signaling to modulate permeability of blood-brain barrier |
US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
-
2013
- 2013-03-15 US US13/837,714 patent/US9050302B2/en active Active
- 2013-04-29 US US13/873,000 patent/US8952029B2/en active Active
- 2013-04-29 US US13/872,997 patent/US8772306B1/en active Active
-
2014
- 2014-02-27 TW TW103106935A patent/TWI619492B/zh active
- 2014-02-28 PL PL14709858T patent/PL2961399T3/pl unknown
- 2014-02-28 JP JP2015560335A patent/JP6433440B2/ja active Active
- 2014-02-28 WO PCT/US2014/019217 patent/WO2014134380A1/en active Application Filing
- 2014-02-28 DK DK17200764.3T patent/DK3335708T3/da active
- 2014-02-28 PT PT172007643T patent/PT3335708T/pt unknown
- 2014-02-28 CN CN201480011891.9A patent/CN105073106A/zh active Pending
- 2014-02-28 EP EP17200764.3A patent/EP3335708B1/en active Active
- 2014-02-28 DK DK14709858.6T patent/DK2961399T3/en active
- 2014-02-28 BR BR112015021012A patent/BR112015021012A8/pt not_active Application Discontinuation
- 2014-02-28 EP EP14709858.6A patent/EP2961399B1/en not_active Revoked
- 2014-02-28 PL PL17200764T patent/PL3335708T3/pl unknown
- 2014-02-28 SI SI201431488T patent/SI3335708T1/sl unknown
- 2014-02-28 ES ES17200764T patent/ES2775779T3/es active Active
- 2014-02-28 LT LTEP17200764.3T patent/LT3335708T/lt unknown
- 2014-02-28 KR KR1020157023426A patent/KR102239042B1/ko active IP Right Grant
- 2014-02-28 CN CN202010091861.0A patent/CN111317730A/zh active Pending
- 2014-02-28 ES ES14709858.6T patent/ES2659284T3/es active Active
- 2014-02-28 AU AU2014223373A patent/AU2014223373B2/en active Active
- 2014-02-28 PT PT147098586T patent/PT2961399T/pt unknown
- 2014-02-28 MX MX2015011242A patent/MX2015011242A/es unknown
- 2014-02-28 SG SG11201505029QA patent/SG11201505029QA/en unknown
- 2014-02-28 EP EP19214483.0A patent/EP3695833A1/en active Pending
- 2014-02-28 CA CA2902948A patent/CA2902948C/en active Active
-
2015
- 2015-05-08 US US14/707,914 patent/US9486426B2/en active Active
- 2015-08-27 IL IL240874A patent/IL240874B/en active IP Right Grant
-
2016
- 2016-03-24 HK HK16103516.1A patent/HK1215539A1/zh not_active IP Right Cessation
- 2016-11-04 US US15/343,806 patent/US20170049731A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,792 patent/US10213400B2/en active Active
- 2018-02-09 CY CY20181100166T patent/CY1120086T1/el unknown
- 2018-12-14 HK HK18116105.8A patent/HK1256965A1/zh unknown
-
2019
- 2019-01-10 US US16/245,067 patent/US10864181B2/en active Active
-
2020
- 2020-02-10 HR HRP20200215TT patent/HRP20200215T1/hr unknown
- 2020-03-06 CY CY20201100199T patent/CY1122992T1/el unknown
- 2020-11-10 US US17/094,778 patent/US20210128502A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/216,540 patent/US11253494B2/en active Active
- 2021-12-27 US US17/562,787 patent/US11986446B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120086T1 (el) | Χορηγηση γαμμα υδροξυβουτυρικου με μεταφορεις μονοκαρβοξυλικου | |
CY1123177T1 (el) | Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη | |
CY1123678T1 (el) | Χρηση αναστολεων μυοστατινης και θεραπειες συνδυασμου | |
CY1124810T1 (el) | Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1120747T1 (el) | Κυκλικες πεπτιδομιμητικες ενωσεις ως ανοσοτροποποιητες | |
SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CL2018002532A1 (es) | Composición farmacéutica que comprende empagliflozina y sus usos | |
BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
BR112016010271A2 (pt) | Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação | |
NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CY1120490T1 (el) | Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων | |
BR112016028643A2 (pt) | ?dispositivo de vedação e sistema de entrega? | |
CY1122113T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου | |
CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
BR112015030399A2 (pt) | derivados heterocíclicos e uso dos mesmos | |
CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
AR096183A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco | |
CY1118214T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει palmitoylethanolamide και l-acetylcarnιτινε | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
BR112017000978A2 (pt) | mioinositol e probióticos e usos | |
CY1124949T1 (el) | Αντισωμα | |
BR112018069927A2 (pt) | terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação | |
CY1122504T1 (el) | Τροφη για πτηνα και ειδικοτερα τροφη για πουλερικα, που περιλαμβανει συνθετικα καψαϊκινοειδη παραγωγα και χρηση της εν λογω τροφης για σκοπους προφυλαξης ή αντιμετωπισης λοιμωξης απο σαλμονελα | |
CY1121773T1 (el) | Χρηση του παλμιτοϋλοαιθανολαμιδιου σε συνδυασμο με οπιοειδη | |
CY1118532T1 (el) | Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης |